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A B S T R A C T   
The development of autoimmune diseases has been reported after SARS-CoV-2 infection. Vaccination against 
SARS-CoV-2 could also trigger auto-immunity, as it has been described with other vaccines. An aberrant immune 
response induced by molecular mimicry and bystander activation, especially in predisposed individuals, is a 
potential mechanism. We report the case of a 76-year-old woman with Hashimoto thyroiditis and prior COVID- 
19 infection who developed severe autoimmune hepatitis (with typical features including strongly positive anti- 
smooth muscle antibody and markedly elevated immunoglobulins G, as well as typical histological findings) 
following SARS-CoV-2 vaccination (mRNA-1273 SARS-CoV-2 vaccine, Moderna®). The link between SARS-CoV- 
2 vaccination and the development of autoimmune diseases needs to be further investigated. Although a cau-
sality relationship cannot be proven, caution may be warranted when vaccinating individuals with known 
autoimmune diseases.   
Article 
A 76-year-old woman was referred to our Hepatology outpatient 
clinic with a 5-week history of dark urine, weight loss and fatigue, 
associated with elevated liver enzymes. Symptoms began two to three 
days after receiving the first dose of the mRNA-1273 SARS-CoV-2 vac-
cine. The patient had a medical history of COVID-19 infection 3 months 
prior (mild disease not requiring hospitalization), Hashimoto thyroiditis 
and prior urothelial carcinoma. Liver enzymes were completely normal 
in a routine check-up three years prior, as well as two months after the 
COVID-19 infection. Drug history included levothyroxine, midodrine 
(for a history of low blood pressure) and zolpidem, which are infre-
quently associated with drug-induced liver injury The patient did not 
take herbal remedies. 
On examination, the patient had discrete scleral and sublingual 
icterus. Abdominal examination was remarkable for tender 
hepatomegaly. 
Laboratory investigations found a total bilirubin of 65 μmol/L, 
elevated aspartate transaminase (811 U/L), alanine transaminase (579 
U/L), alkaline phosphatase (124 U/L) and gamma-glutamyltransferase 
(361 U/L). INR was 1.23 and albumin was 28 g/L. Immunoglobulins 
G (IgG) were significantly increased (39.4 g/L). Anti-nuclear antibody 
(titer 1:1280, homogeneous, fine granular), anti-smooth muscle 
antibody (titer 1:1280, against F-Actin, no specific immunofluorescence 
pattern observed), anti-actin antibody 84 U (negativity cut-off <20 U) 
and anti-neutrophil cytoplasmic antibodies (titer >1:1280, perinuclear, 
MPO and PR3 negative) were strongly positive. Anti-M2 antibody, liver 
kidney microsome type 1 antibody and anti-soluble liver antigen anti-
body were negative. Complete blood count and creatinine were normal. 
Serologies for hepatitis A, B and C viruses were negative. PCR for hep-
atitis B and E viruses and for cytomegalovirus were negative. 
Abdominal ultrasound showed a slightly enlarged and hyper-
echogenic liver without biliary duct dilatation. 
A liver biopsy showed a chronic markedly active hepatitis with 
interface hepatitis, plasma cells, feathery degeneration and pseudoro-
settes (Fig. 1), typical findings of autoimmune hepatitis (AIH). The de-
gree of fibrosis could not be assessed given the significant parenchymal 
collapse. Simplified AIH Score was 8 (definite diagnosis of AIH). 
Treatment with oral prednisolone 40 mg daily was started. Azathi-
oprine was added two weeks later as maintenance therapy. After four 
weeks of treatment, the liver enzymes had completely normalized and 
the patient’s symptoms had significantly improved. A decision was 
made to not administer the second dose of the vaccine. Prednisolone was 
tapered over a total of eight weeks and then stopped. The patient dis-
continued azathioprine on her own after two months of therapy due to 
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drug intolerance and development of a nasal herpes simplex virus 
infection. Six weeks after stopping therapy there were however no 
biochemical signs of an AIH relapse. 
Infections, including with SARS-CoV-2, may induce autoimmunity 
through an aberrant immune response triggered by molecular mimicry 
and bystander activation, especially in predisposed individuals [1–3]. 
Vaccination could, through similar mechanisms, lead to the develop-
ment of autoimmune diseases, but proving such a relationship is chal-
lenging [3,4]. 
Given the close temporal relationship between the vaccination and 
onset of symptoms, we hypothesize that vaccination against COVID-19 
could have triggered the development of AIH in our patient, with 
Hashimoto thyroiditis and prior COVID-19 infection acting as predis-
posing factors. 
This is, to our knowledge, the second report of autoimmune hepatitis 
developing post SARS-CoV-2 vaccination [5], but the first with typical 
serological findings (strongly positive anti-smooth muscle antibody and 
markedly elevated IgG). In the case recently described by Bril et al., only 
anti-nuclear antibody and double-stranded DNA antibodies were posi-
tive and IgG levels were in the normal range. 
While a massive, worldwide vaccination campaign against SARS- 
CoV-2 is occurring, the link between SARS-CoV-2 vaccination and the 
development of autoimmune diseases needs to be further investigated. 
Moreover, the question of whether vaccination should be avoided in 
individuals with severe autoimmune diseases deserves consideration 
[6]. 
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Fig. 1. Histological findings of autoimmune hepatitis after SARS-CoV-2 vacci-
nation. Panel A: Medium-magnification image (hematoxylin-eosin, x5.88) 
showing a chronic, markedly active hepatitis including interface hepatitis. 
Panel B: High-magnification image (hematoxylin-eosin, x23.8) showing plasma 
cells (green arrow), apoptotic bodies (red arrows) and pseudorosettes 
(blue arrows). 
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